Evaluating Safety and Efficacy of Ublituximab in Participants With Schizophrenia
Status: Recruiting
Location: See all (2) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
The main objective of this Phase 2 study is to assess the efficacy of ublituximab as measured by Positive and Negative Syndrome Scale (PANSS) total score in participants with schizophrenia.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 60
Healthy Volunteers: f
View:
• Primary diagnosis of schizophrenia.
• Treatment-resistant.
• Requires antipsychotic treatment and is currently receiving standard of care.
• PANSS total score between 80 and 120, inclusive at screening and baseline.
Locations
United States
Arkansas
TG Therapeutics Investigational Trial Site
RECRUITING
Little Rock
Texas
TG Therapeutics Investigational Trial Site
RECRUITING
Richardson
Contact Information
Primary
TG Therapeutics Clinical Support Team
clinicalsupport@tgtxinc.com
1-877-575-8489
Time Frame
Start Date: 2026-07-27
Estimated Completion Date: 2029-03-01
Participants
Target number of participants: 60
Treatments
Experimental: Ublituximab
Participants will receive ublituximab intravenous (IV) infusion.
Related Therapeutic Areas
Sponsors
Leads: TG Therapeutics, Inc.